1,211
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen

ORCID Icon, , , , , , , & show all
Pages 3484-3492 | Received 03 Jun 2020, Accepted 11 Aug 2020, Published online: 31 Aug 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Lalit Kumar, Ranjit Kumar Sahoo, Sudhir Kumar, Annie K. Baa, Ghazal Tansir, Neha Pathak, Prabhat S. Malik, Om Dutt Sharma, Anisha Mathew, Ankit Jha, Ritu Gupta, Atul Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Soumyaranjan Malik & Ashish Dutt. (2023) Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome. Leukemia & Lymphoma 64:2, pages 378-387.
Read now

Articles from other publishers (3)

瑜 何. (2023) Progress in Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma. Advances in Clinical Medicine 13:02, pages 2563-2568.
Crossref
Mohammad O Ali & Samer Al Hadidi. (2022) High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Transplantation and Cellular Therapy 28:9, pages 572-580.
Crossref
Fei Gao, Mei-Si Lin, Jie-Shu You, Min-Yue Zhang, Long Cheng, Ke Lin, Peng Zhao & Qi-Yan Chen. (2021) Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell International 21:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.